title: [Clinico-neurological and stabilometric analysis of betahistine (betaserc) efficacy in the patients with vertigo in the rehabilitation period of ischemic stroke].
abstract: A study of betahistine (betaserc) in 65 patients aged 59,48 +/- 8,63 years with vertigo in early rehabilitation period of ischemic stroke has been carried out. Thirty-five patients got atiplatelet and antihypertensive therapy and were also treated by betaserc--8-16 mg 3 times per day for 14 days per os, after meals. The control group of 30 patients received only atiplatelet and antihypertensive therapy. Both groups were similar in demographic and clinical characteristics. The treatment with betahistine reduced the intensity and duration of vertigo, led to improvement of coordination and equilibrium, increase stability of a vertical posture that was accompanied by significant (p<0,05) improvement of the values on the Hoffenberth and Bohannon scales. Betahistine treatment also resulted in marked authentic (p<0,05) improvement of stabilometric parameters in biological feedback task that might be explained by activation of the mechanisms maintaining vertical balance. An improvement of clinical and neurophysiologic traits was more pronounced in the group treated with betaserc as compared to the control group.
authors.forename: A B
authors.initials: AB
authors.lastname: Gekht
authors.forename: A B
authors.initials: AB
authors.lastname: Vialkova
authors.forename: D V
authors.initials: DV
authors.lastname: Galanov
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001621:Betahistine / Q000627:therapeutic use*; D001676:Biofeedback, Psychology / Q000187:drug effects / Q000502:physiology*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014715:Vertebrobasilar Insufficiency / Q000150:complications / Q000503:physiopathology* / Q000534:rehabilitation; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D001621:Betahistine